Discovery Laboratories, Inc. announced that the Food and Drug Administration has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis.
NuPathe Inc. announced that the company submitted a New Drug Application for Zelrix to the U.S. Food and Drug Administration. Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.
XOMA Ltd announced several presentations that will highlight advances in the company's biodefense program and particularly in the development of XOMA 3AB, an antibody co-mixture that binds to distinct regions of botulinum toxin type A.
Hyperion Therapeutics, Inc. announced that the company’s phase 3 pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders, met its primary endpoint.
The investigated drug trabedersen (AP 12009) is a gene silencing antisense compound – a phosphorothioate oligodeoxynucleotide – designed to selectively downregulate the production of transforming growth factor-beta 2 (TGF-?2) at the translational level.
Photometrics, a designer and manufacturer of high-performance CCD and EMCCD cameras for the life sciences, has exclusively integrated eXcelon sensor technology in its Evolve 512 and 128 EMCCD cameras.
NanoString Technologies, Inc. announced the launch of a novel solution for detecting genetic copy number variations associated with disease susceptibility, drug response, and cancer progression.
Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.
RecipharmCobra Biologics, an international manufacturer of biopharmaceuticals, announces that the French Ministry for Higher Education and Research has recognised RecipharmCobra as an approved research and development service provider.
Rather than a “one-size-fits-all” treatment plan, researchers say lung cancer patients should receive care based on their specific diagnosis, individual genetic makeup and particular tumors.
Omega-3 pills promoted as boosting memory didn't slow mental and physical decline in older patients with Alzheimer's disease, a big disappointment in a multimillion-dollar government-funded study.
The Food and Drug Administration said it approved Novartis' drug Afinitor to treat some of the tumors caused by a rare genetic disorder called tuberous sclerosis.
Pharmaceutical giant Pfizer Inc. said that revenue in the third quarter jumped 39 percent due to its acquisition of fellow drugmaker Wyeth, but hefty charges related to that $68 billion purchase dragged its profit down 70 percent.
Rubicon Genomics reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing.
Accelrys, Inc. announced the release of version 3.3 of the Isentris data access, analysis, and decision support system. Isentris 3.3 enables scientists to display, manipulate, and compare spectral, chromatographic, and XY graphical data.